FDA Approves Belzutifan Plus Lenvatinib After PD 1 Therapy

Company Merck; Eisai Event Type FDA Approval Modality Small Molecule Combination Asset Belzutifan Plus Lenvatinib Target HIF-2alpha; VEGFR Disease Area Advanced Clear-Cell Renal Cell Carcinoma Summary FDA approved oral belzutifan plus lenvatinib for advanced clear-cell RCC after PD-1 or PD-L1 therapy. In the 747-patient randomized…